Variety of Issues Undermine Efficacy Data As FDA Takes Benlysta To Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III studies focused on lupus patients with less severe disease, throwing into question the drug's efficacy in patients with higher risk of mortality.